Vamotinib is a tyrosine kinase inhibitor and an antineoplastic. Vamotinib is a novel TKI developed with the specifications of (i) targeting T315I and other resistance mutations in BCR/ABL; (ii) achieving a high selectivity to improve safety; and (iii) overcoming nonmutational resistance in Ph+ leukemias. Vamotinib has potential with the treatment of resistant Ph+ leukemia.
MedKoo Cat#: 124482
Name: Vamotinib mesylate
CAS#: 2141996-20-3 (mesylate)
Chemical Formula: C30H31F3N6O4S
Exact Mass: 628.2100
Molecular Weight: 628.67
Elemental Analysis: C, 57.32; H, 4.97; F, 9.07; N, 13.37; O, 10.18; S, 5.10
The following data is based on the product molecular weight 628.67 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
